机构:[1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.[2]Department of Radiation Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Beijing Institute for Cancer Research, Beijing, China.[3]Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.四川省人民医院四川省肿瘤医院[4]Department of Radiation Oncology, Beijing Shijitan Hospital, Capital Medical University, Ninth School of Clinical Medicine, Peking University, School of Oncology, Capital Medical University, Beijing, China.[5]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
第一作者机构:[1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
通讯作者:
推荐引用方式(GB/T 7714):
Han Weiming,Deng Wei,Wang Qifeng,et al.Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma[J].FRONTIERS IN ONCOLOGY.2022,12:doi:10.3389/fonc.2022.998238.
APA:
Han Weiming,Deng Wei,Wang Qifeng,Ni Wenjie,Li Chen...&Xiao Zefen.(2022).Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma.FRONTIERS IN ONCOLOGY,12,
MLA:
Han Weiming,et al."Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma".FRONTIERS IN ONCOLOGY 12.(2022)